>
Switch to:

Orgenesis ROA %

: -32.09% (As of Dec. 2021)
View and export this data going back to 2010. Start your Free Trial

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Orgenesis's annualized Net Income for the quarter that ended in Dec. 2021 was $-20.06 Mil. Orgenesis's average Total Assets over the quarter that ended in Dec. 2021 was $62.52 Mil. Therefore, Orgenesis's annualized ROA % for the quarter that ended in Dec. 2021 was -32.09%.

The historical rank and industry rank for Orgenesis's ROA % or its related term are showing as below:

ORGS' s ROA % Range Over the Past 10 Years
Min: -19992   Med: -31.25   Max: 1.3
Current: -25.05

During the past 13 years, Orgenesis's highest ROA % was 1.30%. The lowest was -19992.00%. And the median was -31.25%.

ORGS's ROA % is ranked better than
58.72% of 1560 companies
in the Biotechnology industry
Industry Median: -31.70 vs ORGS: -25.05

Orgenesis ROA % Historical Data

The historical data trend for Orgenesis's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orgenesis Annual Data
Trend Nov12 Nov13 Nov14 Nov15 Nov16 Nov17 Nov18 Dec19 Dec20 Dec21
ROA %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -33.72 -31.72 -28.73 1.30 -26.25

Orgenesis Quarterly Data
Feb17 May17 Aug17 Nov17 Feb18 May18 Aug18 Nov18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21
ROA % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -195.45 -1.10 -13.49 -57.74 -32.09

Competitive Comparison

For the Biotechnology subindustry, Orgenesis's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Orgenesis ROA % Distribution

For the Biotechnology industry and Healthcare sector, Orgenesis's ROA % distribution charts can be found below:

* The bar in red indicates where Orgenesis's ROA % falls into.



Orgenesis ROA % Calculation

Orgenesis's annualized ROA % for the fiscal year that ended in Dec. 2021 is calculated as:

ROA %=Net Income (A: Dec. 2021 )/( (Total Assets (A: Dec. 2020 )+Total Assets (A: Dec. 2021 ))/ count )
=-18.053/( (77.684+59.841)/ 2 )
=-18.053/68.7625
=-26.25 %

Orgenesis's annualized ROA % for the quarter that ended in Dec. 2021 is calculated as:

ROA %=Net Income (Q: Dec. 2021 )/( (Total Assets (Q: Sep. 2021 )+Total Assets (Q: Dec. 2021 ))/ count )
=-20.064/( (65.204+59.841)/ 2 )
=-20.064/62.5225
=-32.09 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Dec. 2021) net income data. ROA % is displayed in the 30-year financial page.


Orgenesis  (NAS:ORGS) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Dec. 2021 )
=Net Income/Total Assets
=-20.064/62.5225
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-20.064 / 27.568)*(27.568 / 62.5225)
=Net Margin %*Asset Turnover
=-72.78 %*0.4409
=-32.09 %

Note: The Net Income data used here is four times the quarterly (Dec. 2021) net income data. The Revenue data used here is four times the quarterly (Dec. 2021) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Orgenesis ROA % Related Terms

Thank you for viewing the detailed overview of Orgenesis's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


Orgenesis Business Description

Orgenesis logo
Industry
Healthcare » Biotechnology NAICS : 325412 SIC : 2834
Traded in Other Exchanges
Address
20271 Goldenrod Lane, Germantown, MD, USA, 20876
Orgenesis Inc is a part of the healthcare sector. It is a fully-integrated biopharmaceutical company focused on developing trans-differentiation technologies for diabetes and vertically integrating manufacturing that can optimize its abilities to scale-up its technologies for clinical trials and eventual commercialization. The group operates in two segments namely CDMO and POC. The company is also engaged in applying its disciplined execution to emerging technologies of other cell therapy markets in such areas as cell-based cancer immunotherapies and neurodegenerative diseases.
Executives
Sidransky David director JOHNS HOPKINS UNIVERSITY 720 RUTLAND AVENUE BALTIMORE MD 21205
Reithinger Neil officer: CFO, Treasurer and Secretary 14950 N. 83RD PLACE SUITE 1 SCOTTSDALE AZ 85260
Philips Mario director C/O ATMI, INC DANBURY CT 06810
Ferber Sarah officer: Chief Scientific Officer 17B HAHASKALA STREET TEL AVIV L3 67890
Yachin Guy director 7 ORCHARD WAY N POTOMAC MD 20854
Nanda Ashish director 2301, 23RD FLOOR, TIFFANY TOWERS CLUSTER W, JLT, DUBAI, UAE DUBAI C0 4452
Bedoret Denis officer: See Remarks 48, RUE AUGUSTE PICCARD GOSSELIES C9 6041
Universite Libre De Bruxelles other: less than 10% AVENUE F, ROOSEVELT, 50 BRUSSELS C9 1050
Theodorus Ii Sa other: less than 10% ALLEE DE LA RECHERCHE, 12 BRUSSELS C9 1070
Theodorus Sca other: less than 10% ALLEE DE LA RECHERCHE, 12 BRUSSELS C9 1070
Belenger Olivier other: less than 10% DIEWEG, 69 BRUSSELS C9 1070
Shvartz Oded 10 percent owner 130 BIRUINTEI BVD. PANTELIMON, ILFOV S5 0000000
Bultot Hugues director AVENUE DE L??HORIZON 24 WOLUWE SAINT PIERRE C9 1150
Buyse Chris Georges Frans director BAILLET LATOURLEI 119A BRUSSELS C9 2390
Tenne Joseph officer: CFO Treasurer Secretary 6225 NEIL ROAD, SUITE 300 C/O ORMAT TECHNOLOGIES, INC. RENO NV 89511

Orgenesis Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)